Order Article Reprints

Baier D, Schoenhacker-Alte B, Rusz M, Pirker C, Mohr T, Mendrina T, Kirchhofer D, Meier-Menches SM, Hohenwallner K, Schaier M, et al. The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics. 2022; 14(2):238. https://doi.org/10.3390/pharmaceutics14020238

Baier, Dina, Beatrix Schoenhacker-Alte, Mate Rusz, Christine Pirker, Thomas Mohr, Theresa Mendrina, Dominik Kirchhofer, Samuel M. Meier-Menches, Katharina Hohenwallner, Martin Schaier, and et al. 2022. "The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation" Pharmaceutics 14, no. 2: 238. https://doi.org/10.3390/pharmaceutics14020238

Baier, D., Schoenhacker-Alte, B., Rusz, M., Pirker, C., Mohr, T., Mendrina, T., Kirchhofer, D., Meier-Menches, S. M., Hohenwallner, K., Schaier, M., Rampler, E., Koellensperger, G., Heffeter, P., Keppler, B., & Berger, W. (2022). The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics, 14(2), 238. https://doi.org/10.3390/pharmaceutics14020238